The estimated Net Worth of Sara N Ortwein is at least $8.49 Millón dollars as of 15 December 2016. Sara Ortwein owns over 5,000 units of Sanara MedTech stock worth over $7,581,939 and over the last 8 years Sara sold SMTI stock worth over $908,800.
Sara has made over 2 trades of the Sanara MedTech stock since 2016, according to the Form 4 filled with the SEC. Most recently Sara sold 5,000 units of SMTI stock worth $454,400 on 15 December 2016.
The largest trade Sara's ever made was selling 5,000 units of Sanara MedTech stock on 15 December 2016 worth over $454,400. On average, Sara trades about 667 units every 0 days since 2016. As of 15 December 2016 Sara still owns at least 226,259 units of Sanara MedTech stock.
You can see the complete history of Sara Ortwein stock trades at the bottom of the page.
Sara's mailing address filed with the SEC is 1200 SUMMIT AVE, SUITE 414, FORT WORTH, TX, 76102.
Over the last 5 years, insiders at Sanara MedTech have traded over $168,795 worth of Sanara MedTech stock. The most active insiders traders include Eric D Tanzberger, Ronald T Nixon y James W Stuckert. On average, Sanara MedTech executives and independent directors trade stock every 55 days with the average trade being worth of $25,133. The most recent stock trade was executed by Michael D. Mc Neil on 12 April 2023, trading 1,000 units of SMTI stock currently worth $6,000.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Sanara MedTech executives and other stock owners filed with the SEC include: